In our study, we reviewed the CD34 expression in GG with epilepsy and found 88.5% of tumors were CD34 positive, which was line with the previous studies (Deb et al., 2006; Chappé et al., 2013; Giulioni et al., 2019). Here, CD34 is linked to epilepsy.